Back to search
Recurrent B-Cell Non-Hodgkin Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent B-Cell Non-Hodgkin Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent B-Cell Non-Hodgkin Lymphoma trials you may qualify forThis is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer age…
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with ot…
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-tar…
This study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the rec…
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with la…
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on partic…
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer…
This phase I trial studies the side effects and best dose of lenalidomide and ibrutinib in treating patients with B-cell non-Hodgkin lymphoma that has returned…